Details of Disease

General Information of Disease (ID: DIS6HNYO)

Disease Name	Testicular cancer
Synonyms	paediatric testicular neoplasm; testicular tumour; testis neoplasm; testicular tumor; malignant tumor of the testis; malignant tumour of the testis; testis cancer; malignant testicular neoplasm; cancer of testis; malignant testicular tumor; malignant tumor of testis; malignant neoplasm of testis; malignant neoplasm of the testis; malignant testicular tumour; malignant testis neoplasm; malignant tumour of testis
Disease Class	2C80: Testicular cancer
Definition	A primary or metastatic malignant neoplasm that affects the testis. Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.
Disease Hierarchy	DIS0RQDP: Male reproductive organ cancer DISK4XHT: Neoplasm of testis DISAT1Z9: Advanced cancer DIS6HNYO: Testicular cancer
ICD Code	ICD-11 ICD-11: 2C80 ICD-9 ICD-9: 186 Expand ICD-11 '2C80 Expand ICD-10 'C62; 'C62.0; 'C62.1; 'C62.9 Expand ICD-9 186
Disease Identifiers	MONDO ID MONDO_0005447 MESH ID D013736 UMLS CUI C0153594 MedGen ID 56313 SNOMED CT ID 363449006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bavencio	DMU9C8F	Approved	Monoclonal antibody	[1]
Etoposide	DMNH3PG	Approved	Small molecular drug	[2]
Plicamycin	DM7C8YV	Approved	Small molecular drug	[3]
Vinblastine	DM5TVS3	Approved	Small molecular drug	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
(+)-JQ1	DM1CZSJ	Phase 1	Small molecular drug	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 24 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CACNA1F	TTJ0SO4	Limited	Altered Expression	[6]
ITGA4	TTJMF9P	Limited	Genetic Variation	[7]
KITLG	TTDJ51N	Limited	Genetic Variation	[8]
AFP	TTCFEA1	moderate	Biomarker	[9]
BAP1	TT47RXJ	moderate	Biomarker	[10]
CTDSP1	TTHZAF0	moderate	Altered Expression	[11]
KLK14	TTDA81R	moderate	Biomarker	[12]
PLAC1	TTM18HX	moderate	Biomarker	[13]
ATXN3	TT6A17J	Strong	Biomarker	[14]
CTAG1A	TTE5ITK	Strong	Biomarker	[15]
CTCFL	TTY0RZT	Strong	Biomarker	[16]
FSHR	TTZFDBT	Strong	Genetic Variation	[17]
KIT	TTX41N9	Strong	Genetic Variation	[18]
LY6K	TT5GKHN	Strong	Biomarker	[19]
MAGEA1	TT63M7Q	Strong	Biomarker	[16]
MAGEA10	TT1VNVM	Strong	Genetic Variation	[20]
MAGEA3	TTWSKHD	Strong	Biomarker	[21]
MAGEC2	TTKGUEB	Strong	Biomarker	[22]
MLANA	TT362RB	Strong	Biomarker	[23]
PDE11A	TTTWC79	Strong	Biomarker	[24]
SLCO1B3	TTU86P0	Strong	Altered Expression	[25]
MAGEA4	TT9EQUY	Definitive	Altered Expression	[26]
NUF2	TTIXBFP	Definitive	Biomarker	[27]
SULF2	TTLQTHB	Definitive	Altered Expression	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 24 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A5	DT3I124	Strong	Biomarker	[29]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP3A7	DERD86B	Strong	Genetic Variation	[30]
PCYT1A	DEQYXD4	Strong	Biomarker	[31]
------------------------------------------------------------------------------------

This Disease Is Related to 86 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PCDH11X	OTLICG18	Limited	Genetic Variation	[7]
SEMG1	OT6Z4BPQ	Limited	Altered Expression	[32]
ACTL8	OTUDD0QT	moderate	Biomarker	[33]
CT45A1	OT80VTZO	moderate	Biomarker	[34]
CTAG2	OT8HISP4	moderate	Genetic Variation	[20]
FMR1NB	OT5IC2M2	moderate	Biomarker	[35]
INSL3	OT7KUNTE	moderate	Altered Expression	[36]
PANX1	OTXPEDOK	moderate	Biomarker	[37]
SCPEP1	OT43LYEZ	moderate	Altered Expression	[11]
SPANXB1	OTLMGC9T	moderate	Biomarker	[38]
SPANXC	OT1033B9	moderate	Altered Expression	[39]
SSX1	OTZ7NRCY	moderate	Altered Expression	[40]
SSX4	OT0E4H2D	moderate	Altered Expression	[11]
STK31	OT3ZLRH0	moderate	Biomarker	[41]
SYCP1	OTWFV4KA	moderate	Altered Expression	[11]
AADAC	OT8VACT2	Strong	Altered Expression	[42]
ACRBP	OT0MK3L1	Strong	Biomarker	[43]
ADAM2	OT62YCDZ	Strong	Altered Expression	[44]
AKAP3	OT42QOFG	Strong	Biomarker	[45]
AKAP4	OTL4Z99V	Strong	Biomarker	[46]
ANKRD36B	OT3MW415	Strong	Altered Expression	[15]
ARSL	OTF1VTCR	Strong	Genetic Variation	[47]
CABYR	OTKYMT99	Strong	Biomarker	[48]
CCDC54	OTW5WCX9	Strong	Biomarker	[49]
CCDC83	OTF1ETS6	Strong	Biomarker	[50]
CCNA1	OTX4HD45	Strong	Altered Expression	[51]
CCNK	OTZ7JBPK	Strong	Altered Expression	[52]
CETN1	OTGQ8JOZ	Strong	Biomarker	[53]
CFHR2	OTACE5Y1	Strong	Genetic Variation	[54]
CHGB	OT7SAQT2	Strong	Altered Expression	[32]
CT55	OTQC0H27	Strong	Biomarker	[55]
CTAG1B	OTIQGW6U	Strong	Biomarker	[15]
DCAF12	OT24XM7T	Strong	Biomarker	[56]
DDX43	OTK1RYSK	Strong	Altered Expression	[57]
DMRT1	OT5PU9U1	Strong	Genetic Variation	[58]
DNAH7	OTTI8FRY	Strong	Biomarker	[59]
ERCC1	OTNPYQHI	Strong	Biomarker	[60]
ERCC4	OTFIOPG1	Strong	Altered Expression	[61]
EXO5	OTIN7L7I	Strong	Biomarker	[59]
EXOSC5	OTADUQ7H	Strong	Biomarker	[62]
FAM133A	OTO75ZO4	Strong	Biomarker	[63]
FBXW4	OTEGSZOX	Strong	Altered Expression	[42]
GDF1	OTZ1VRBH	Strong	Genetic Variation	[47]
INHA	OT7HWCO3	Strong	Biomarker	[64]
KLK11	OT5PKX7Y	Strong	Biomarker	[12]
KLK13	OT8LOD2U	Strong	Genetic Variation	[65]
LARP6	OTUQ9QS9	Strong	Genetic Variation	[66]
LEMD1	OTII3FTO	Strong	Biomarker	[67]
LUZP4	OTXC3EYH	Strong	Biomarker	[11]
MAGED4B	OTO37U7W	Strong	Genetic Variation	[20]
MEIOB	OTTX5TF0	Strong	Biomarker	[68]
MYO5A	OTMWLP3E	Strong	Altered Expression	[69]
NDN	OTYBYJ82	Strong	Altered Expression	[70]
NDUFS1	OTTIZDFR	Strong	Altered Expression	[71]
NXF2	OTJS5KTH	Strong	Biomarker	[72]
PASD1	OTZZWR7L	Strong	Biomarker	[73]
PIWIL2	OT1PXQIF	Strong	Biomarker	[74]
POTED	OTAUSTUK	Strong	Biomarker	[31]
RHOXF2	OTKQWLKZ	Strong	Biomarker	[75]
RNF17	OTKOEPRW	Strong	Biomarker	[76]
RNH1	OT6EC79B	Strong	Genetic Variation	[47]
RXFP2	OT7SAT9U	Strong	Genetic Variation	[77]
SCGB3A1	OTIR98RB	Strong	Biomarker	[78]
SHC3	OT305NPA	Strong	Genetic Variation	[47]
SPA17	OT8J7T7U	Strong	Biomarker	[49]
SPACA3	OTM1JKTC	Strong	Biomarker	[79]
SPAG17	OTUF58WZ	Strong	Biomarker	[80]
SPAG9	OT45AHMB	Strong	Biomarker	[81]
SPANXA1	OTMK3QIS	Strong	Biomarker	[82]
SSX2	OT2Z6RLL	Strong	Biomarker	[83]
STK11	OT1YZSP3	Strong	Genetic Variation	[84]
TAF9	OTCTH3C6	Strong	Biomarker	[85]
TDRD1	OT0CBCI3	Strong	Biomarker	[76]
TDRD5	OTYSOQS0	Strong	Biomarker	[76]
TEKT5	OTZ5OUHY	Strong	Biomarker	[86]
TFDP3	OTI4K6MN	Strong	Biomarker	[87]
TMEFF1	OTH6M3CH	Strong	Altered Expression	[49]
TMEM31	OTKDPZD4	Strong	Biomarker	[88]
TRO	OTRZQMU8	Strong	Altered Expression	[89]
TSGA10	OTIF1O1T	Strong	Biomarker	[90]
TSPY1	OTPY57X4	Strong	Biomarker	[91]
TSPY3	OTQK3AKI	Strong	Biomarker	[91]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[92]
CCDC62	OTTIAOBP	Definitive	Biomarker	[93]
CT83	OTQEGHAB	Definitive	Genetic Variation	[94]
SULF1	OTJCNCO0	Definitive	Altered Expression	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 86 DOT(s)

References

1	ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
2	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Vinblastine FDA Label
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.PLoS One. 2015 Jul 6;10(7):e0125766. doi: 10.1371/journal.pone.0125766. eCollection 2015.
7	Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer.Nat Genet. 2009 Jul;41(7):811-5. doi: 10.1038/ng.393. Epub 2009 May 31.
8	A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation.J Med Genet. 2012 Jan;49(1):58-65. doi: 10.1136/jmedgenet-2011-100174. Epub 2011 Dec 3.
9	Glycan Analysis as Biomarkers for Testicular Cancer.Diagnostics (Basel). 2019 Oct 22;9(4):156. doi: 10.3390/diagnostics9040156.
10	Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
11	Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.Int J Cancer. 2006 Feb 1;118(3):696-703. doi: 10.1002/ijc.21352.
12	Human tissue kallikrein gene family: applications in cancer.Cancer Lett. 2005 Jun 16;224(1):1-22. doi: 10.1016/j.canlet.2004.09.024.
13	PLAC1: biology and potential application in cancer immunotherapy.Cancer Immunol Immunother. 2019 Jul;68(7):1039-1058. doi: 10.1007/s00262-019-02350-8. Epub 2019 Jun 5.
14	Ataxin-3 promotes testicular cancer cell proliferation by inhibiting anti-oncogene PTEN.Biochem Biophys Res Commun. 2018 Sep 3;503(1):391-396. doi: 10.1016/j.bbrc.2018.06.047. Epub 2018 Jun 18.
15	Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett. 2019 Apr;17(4):3937-3943. doi: 10.3892/ol.2019.10044. Epub 2019 Feb 14.
16	MAGEA1 inhibits the expression of BORIS via increased promoter methylation.J Cell Sci. 2019 Jan 2;132(1):jcs218628. doi: 10.1242/jcs.218628.
17	Analysis of single nucleotide polymorphisms of FSH receptor gene suggests association with testicular cancer susceptibility.Endocr Relat Cancer. 2008 Jun;15(2):429-37. doi: 10.1677/ERC-07-0257. Epub 2008 Apr 22.
18	Somatic mutations of KIT in familial testicular germ cell tumours.Br J Cancer. 2004 Jun 14;90(12):2397-401. doi: 10.1038/sj.bjc.6601880.
19	Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.Cancer Res. 2007 Dec 15;67(24):11601-11. doi: 10.1158/0008-5472.CAN-07-3243.
20	Pattern of cancer/testis antigen expression in lung cancer patients.Int J Mol Med. 2012 Apr;29(4):656-62. doi: 10.3892/ijmm.2012.896. Epub 2012 Jan 24.
21	MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.Cancers (Basel). 2019 May 15;11(5):677. doi: 10.3390/cancers11050677.
22	Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.Virchows Arch. 2020 Apr;476(4):535-542. doi: 10.1007/s00428-019-02661-2. Epub 2019 Sep 2.
23	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.J Transl Med. 2018 Jul 4;16(1):184. doi: 10.1186/s12967-018-1563-y.
24	Rare inactivating PDE11A variants associated with testicular germ cell tumors.Endocr Relat Cancer. 2015 Dec;22(6):909-17. doi: 10.1530/ERC-15-0034.
25	Expression of OATP family members in hormone-related cancers: potential markers of progression.PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.
26	MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.Virchows Arch. 2017 Sep;471(3):383-392. doi: 10.1007/s00428-017-2206-z. Epub 2017 Jul 26.
27	HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.Int J Cancer. 2008 Dec 1;123(11):2616-25. doi: 10.1002/ijc.23823.
28	SULFs in human neoplasia: implication as progression and prognosis factors.J Transl Med. 2011 May 21;9:72. doi: 10.1186/1479-5876-9-72.
29	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562.
30	CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.Int J Androl. 2011 Feb;34(1):77-83. doi: 10.1111/j.1365-2605.2010.01057.x.
31	Epigenetic activation of POTE genes in ovarian cancer.Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.
32	Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
33	High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.Mol Med Rep. 2019 Feb;19(2):877-884. doi: 10.3892/mmr.2018.9716. Epub 2018 Dec 3.
34	CT45A1 siRNA silencing suppresses the proliferation, metastasis and invasion of lung cancer cells by downregulating the ERK/CREB signaling pathway.Mol Med Rep. 2017 Nov;16(5):6708-6714. doi: 10.3892/mmr.2017.7466. Epub 2017 Sep 12.
35	A cancer/testis antigen, NY-SAR-35, induces EpCAM, CD44, and CD133, and activates ERK in HEK293 cells.Biochem Biophys Res Commun. 2017 Mar 4;484(2):298-303. doi: 10.1016/j.bbrc.2017.01.105. Epub 2017 Jan 23.
36	Expression patterns of DLK1 and INSL3 identify stages of Leydig cell differentiation during normal development and in testicular pathologies, including testicular cancer and Klinefelter syndrome.Hum Reprod. 2014 Aug;29(8):1637-50. doi: 10.1093/humrep/deu124. Epub 2014 Jun 7.
37	In vitro effect of Pannexin 1 channel on the invasion and migration of I-10 testicular cancer cells via ERK1/2 signaling pathway.Biomed Pharmacother. 2019 Sep;117:109090. doi: 10.1016/j.biopha.2019.109090. Epub 2019 Jun 12.
38	Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.Sci Rep. 2019 Aug 12;9(1):11632. doi: 10.1038/s41598-019-48064-w.
39	Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma.J Cell Mol Med. 2019 Nov;23(11):7261-7267. doi: 10.1111/jcmm.14532. Epub 2019 Sep 4.
40	Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.Oncol Rep. 2009 Mar;21(3):713-9.
41	STK31 as novel biomarker of metastatic potential and tumorigenicity of colorectal cancer.Oncotarget. 2017 Apr 11;8(15):24354-24361. doi: 10.18632/oncotarget.15396.
42	Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.Tumour Biol. 2014 Jun;35(6):5753-62. doi: 10.1007/s13277-014-1764-9. Epub 2014 Mar 2.
43	Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.Int J Clin Exp Pathol. 2015 Jul 1;8(7):7786-97. eCollection 2015.
44	Identification of cancer/testis genes by database mining and mRNA expression analysis.Int J Cancer. 2002 Apr 1;98(4):485-92. doi: 10.1002/ijc.10276.
45	Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma.Oncol Rep. 2012 Nov;28(5):1792-8. doi: 10.3892/or.2012.2002. Epub 2012 Aug 30.
46	Role of A-Kinase anchor protein (AKAP4) in growth and survival of ovarian cancer cells.Oncotarget. 2017 May 24;8(32):53124-53136. doi: 10.18632/oncotarget.18163. eCollection 2017 Aug 8.
47	Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer.Cancer Lett. 2005 Jul 28;225(2):245-51. doi: 10.1016/j.canlet.2005.03.021.
48	CABYR is a novel cancer-testis antigen in lung cancer.Clin Cancer Res. 2007 Feb 15;13(4):1288-97. doi: 10.1158/1078-0432.CCR-06-1742.
49	Cancer-testis antigens as biomarkers for Merkel cell carcinoma: Pitfalls and opportunities.J Cutan Pathol. 2019 Oct;46(10):748-752. doi: 10.1111/cup.13528. Epub 2019 Jul 11.
50	KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer.Int J Oncol. 2012 Nov;41(5):1820-6. doi: 10.3892/ijo.2012.1601. Epub 2012 Aug 22.
51	E- and A-type cyclins as markers for cancer diagnosis and prognosis.Expert Rev Mol Diagn. 2003 Sep;3(5):617-33. doi: 10.1586/14737159.3.5.617.
52	A distinct expression pattern of cyclin K in mammalian testes suggests a functional role in spermatogenesis.PLoS One. 2014 Jul 8;9(7):e101539. doi: 10.1371/journal.pone.0101539. eCollection 2014.
53	Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.Cancer Med. 2019 Sep;8(11):5289-5300. doi: 10.1002/cam4.2379. Epub 2019 Jul 16.
54	Age-specific familial risks in common cancers of the offspring.Int J Cancer. 1998 Oct 5;78(2):172-5. doi: 10.1002/(sici)1097-0215(19981005)78:2<172::aid-ijc9>3.0.co;2-w.
55	Cancer testis antigen 55 deficiency attenuates colitis-associated colorectal cancer by inhibiting NF-B signaling.Cell Death Dis. 2019 Apr 3;10(4):304. doi: 10.1038/s41419-019-1537-x.
56	Novel centrosome protein, TCC52, is a cancer-testis antigen.Cancer Sci. 2008 Nov;99(11):2274-9. doi: 10.1111/j.1349-7006.2008.00937.x. Epub 2008 Oct 14.
57	Frequent expression of HAGE in presentation chronic myeloid leukaemias.Leukemia. 2002 Nov;16(11):2238-42. doi: 10.1038/sj.leu.2402732.
58	A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility.Hum Mol Genet. 2011 Aug 1;20(15):3109-17. doi: 10.1093/hmg/ddr207. Epub 2011 May 6.
59	Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer.Int J Cancer. 2018 Oct 15;143(8):1954-1962. doi: 10.1002/ijc.31604. Epub 2018 Aug 9.
60	ERCC1 and XPF expression in human testicular germ cell tumors.Oncol Rep. 2010 Jan;23(1):223-7.
61	Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma.Int J Cancer. 2016 Dec 15;139(12):2827-2837. doi: 10.1002/ijc.30396. Epub 2016 Sep 16.
62	Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.Cancer Immunol Immunother. 2006 Dec;55(12):1575-83. doi: 10.1007/s00262-006-0152-8. Epub 2006 Mar 14.
63	Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.Cancer Lett. 2018 Sep 28;432:93-102. doi: 10.1016/j.canlet.2018.06.007. Epub 2018 Jun 6.
64	The inhibin/activin signalling pathway in human gonadal and adrenal cancers.Mol Hum Reprod. 2014 Dec;20(12):1223-37. doi: 10.1093/molehr/gau074. Epub 2014 Sep 1.
65	Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer.Anticancer Res. 2001 Sep-Oct;21(5):3147-52.
66	The study of PSA gene expression on urogenital cell lines.Int J Urol. 1999 Oct;6(10):526-31. doi: 10.1046/j.1442-2042.1999.00104.x.
67	Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.Biochem Biophys Res Commun. 2017 Apr 8;485(3):651-657. doi: 10.1016/j.bbrc.2017.02.081. Epub 2017 Feb 20.
68	Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells.Immunol Lett. 2014 Mar-Apr;158(1-2):175-82. doi: 10.1016/j.imlet.2014.01.004. Epub 2014 Jan 16.
69	Myosin Va plays essential roles in maintaining normal mitosis, enhancing tumor cell motility and viability.Oncotarget. 2017 May 17;8(33):54654-54671. doi: 10.18632/oncotarget.17920. eCollection 2017 Aug 15.
70	Cancer/testis antigens: structural and immunobiological properties.Cancer Invest. 2002;20(2):222-36. doi: 10.1081/cnv-120001150.
71	Altered Molecular Pathways in the Proteome of Cryopreserved Sperm in Testicular Cancer Patients before Treatment.Int J Mol Sci. 2019 Feb 5;20(3):677. doi: 10.3390/ijms20030677.
72	The cancertestis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.Mol Med Rep. 2013 Nov;8(5):1549-55. doi: 10.3892/mmr.2013.1659. Epub 2013 Aug 28.
73	DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.Leukemia. 2010 Nov;24(11):1951-9. doi: 10.1038/leu.2010.196. Epub 2010 Sep 23.
74	The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.Cancer Immunol Immunother. 2013 Nov;62(11):1723-32. doi: 10.1007/s00262-013-1478-7.
75	Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies.PLoS One. 2016 Jan 19;11(1):e0146371. doi: 10.1371/journal.pone.0146371. eCollection 2016.
76	Tudor domain-containing protein 4 as a potential cancer/testis antigen in liver cancer.Tohoku J Exp Med. 2011 May;224(1):41-6. doi: 10.1620/tjem.224.41.
77	Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization.Mol Hum Reprod. 2006 Jun;12(6):401-6. doi: 10.1093/molehr/gal043. Epub 2006 May 10.
78	Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1).J Pathol. 2006 Dec;210(4):441-9. doi: 10.1002/path.2064.
79	The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.Clin Cancer Res. 2004 Oct 1;10(19):6544-50. doi: 10.1158/1078-0432.CCR-04-0911.
80	Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.J Immunother. 2011 Jan;34(1):28-44. doi: 10.1097/CJI.0b013e3181fb64fa.
81	SPAG9 promotes prostate cancer proliferation and metastasis via MAPK signaling pathway.Am J Transl Res. 2019 Aug 15;11(8):5249-5260. eCollection 2019.
82	Mutational analysis of SPANX genes in families with X-linked prostate cancer.Prostate. 2007 Jun 1;67(8):820-8. doi: 10.1002/pros.20561.
83	A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4?and CD8?T-cell as well as B-cell responses.Cancer Immunol Immunother. 2011 Sep;60(9):1333-46. doi: 10.1007/s00262-011-1030-6. Epub 2011 Jun 1.
84	Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors.Cancer Res. 1998 May 15;58(10):2087-90.
85	Cancertestis antigen HCA587/MAGEC2 interacts with the general transcription coactivator TAF9 in cancer cells.Mol Med Rep. 2018 Feb;17(2):3226-3231. doi: 10.3892/mmr.2017.8260. Epub 2017 Dec 12.
86	Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity.BMC Cancer. 2012 Nov 14;12:520. doi: 10.1186/1471-2407-12-520.
87	Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells.Br J Cancer. 2004 Apr 19;90(8):1636-43. doi: 10.1038/sj.bjc.6601706.
88	Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression.Oncol Lett. 2017 Apr;13(4):2269-2273. doi: 10.3892/ol.2017.5728. Epub 2017 Feb 13.
89	Functional correlation of trophinin expression with the malignancy of testicular germ cell tumor.Cancer Res. 2004 Jun 15;64(12):4257-62. doi: 10.1158/0008-5472.CAN-04-0732.
90	Identification of new TSGA10 transcript variants in human testis with conserved regulatory RNA elements in 5'untranslated region and distinct expression in breast cancer.Biochim Biophys Acta Gene Regul Mech. 2017 Sep;1860(9):973-982. doi: 10.1016/j.bbagrm.2017.07.007. Epub 2017 Jul 21.
91	TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma.Br J Cancer. 2005 Aug 22;93(4):458-63. doi: 10.1038/sj.bjc.6602716.
92	Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer.Nat Genet. 2010 Jul;42(7):604-7. doi: 10.1038/ng.607. Epub 2010 Jun 13.
93	Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity.Int J Cancer. 2009 May 15;124(10):2347-52. doi: 10.1002/ijc.24220.
94	Cancer/testis antigen expression as a predictor for epidermal growth factor receptor mutation and prognosis in lung adenocarcinoma.Eur J Cardiothorac Surg. 2013 Apr;43(4):759-64. doi: 10.1093/ejcts/ezs426. Epub 2012 Jul 22.